Regen Biopharma INC (RGBPP) — SEC Filings

Q: What are the key financial highlights for Regen Biopharma INC?

Key financial highlights for Regen Biopharma INC are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Regen Biopharma INC?

Key executives at Regen Biopharma INC are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Regen Biopharma INC stock?

Risk factors for Regen Biopharma INC (RGBPP) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Regen Biopharma INC?

Forward-looking statements and predictions from Regen Biopharma INC are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Regen Biopharma INC. Recent 10-K filing on Dec 30, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Regen Biopharma INC on SEC EDGAR

Overview

Regen Biopharma INC (RGBPP) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Dec 30, 2025: Regen BioPharma Inc. (RGBPP) reported no revenue for the fiscal year ending September 30, 2025, as it remains a development-stage biotechnology company focused on regenerative medical applications. The company is advancing several therapies, including HemaXellarate for aplastic anemia, dCellVax and

Sentiment Summary

Across 23 filings, the sentiment breakdown is: 3 bearish, 20 neutral. The dominant filing sentiment for Regen Biopharma INC is neutral.

Filing Type Overview

Regen Biopharma INC (RGBPP) has filed 2 10-K, 15 8-K, 6 10-Q with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (23)

Regen BioPharma: No Revenue, Focus on Early-Stage Biotech Pipeline — 10-K · Dec 30, 2025 Risk: high
Regen BioPharma Inc. (RGBPP) reported no revenue for the fiscal year ending September 30, 2025, as it remains a development-stage biotechnology company focused
8-K Filing — 8-K · Nov 13, 2025
Regen BioPharma Files 8-K: Material Agreement & Equity Sales — 8-K · Oct 3, 2025 Risk: medium
On October 2, 2025, Regen BioPharma Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and
Regen BioPharma Reports Unregistered Equity Sales — 8-K · Sep 19, 2025 Risk: medium
Regen BioPharma Inc. filed an 8-K on September 19, 2025, reporting unregistered sales of equity securities as of September 15, 2025. The filing does not specify
Regen BioPharma Narrows Q3 Loss to $1,000 Amidst Zero Revenue — 10-Q · Aug 11, 2025 Risk: high
Regen BioPharma Inc. reported no revenue for the three and nine months ended June 30, 2025, consistent with the prior year periods. The company incurred a net l
Regen BioPharma Files 8-K for Material Agreement — 8-K · Aug 7, 2025 Risk: medium
Regen BioPharma Inc. announced on August 5, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales of equit
Regen BioPharma Inc. Files 8-K with Material Agreements — 8-K · Aug 1, 2025 Risk: medium
On July 28, 2025, Regen BioPharma Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and fi
Regen BioPharma Reports Unregistered Equity Sales — 8-K · Jun 11, 2025 Risk: medium
Regen BioPharma Inc. filed an 8-K on June 11, 2025, reporting unregistered sales of equity securities. The filing details events that occurred on June 10, 2025,
Regen BioPharma Narrows Losses Amidst Zero Revenue, Equity Raises — 10-Q · May 28, 2025 Risk: high
Regen BioPharma Inc. reported no revenue for the three and six months ended March 31, 2025, consistent with the prior year periods. The company incurred a net l
Regen BioPharma Files Q1 2025 10-Q — 10-Q · May 16, 2025 Risk: medium
Regen BioPharma Inc. filed its 10-Q for the period ending December 31, 2024. The filing covers the first quarter of their fiscal year, which began on October 1,
Regen BioPharma Files 2024 10-K — 10-K · May 13, 2025 Risk: medium
Regen BioPharma Inc. filed its 10-K for the fiscal year ending September 30, 2024, reporting on its operations and financial condition. The company, incorporate
Regen BioPharma Changes Auditors — 8-K · Apr 7, 2025 Risk: medium
Regen BioPharma Inc. announced on March 31, 2025, a change in its certifying accountant. The company has dismissed its previous independent registered public ac
Regen BioPharma Files 8-K on Financials — 8-K · Nov 29, 2024 Risk: low
Regen BioPharma Inc. filed an 8-K on November 29, 2024, reporting on its financial condition and results of operations as of September 30, 2024. The filing deta
Regen BioPharma to Acquire 03 Life Sciences — 8-K · Sep 18, 2024 Risk: medium
Regen BioPharma Inc. announced on September 18, 2024, that it has entered into a definitive agreement to acquire all of the outstanding equity interests of 03 L
Regen BioPharma Inc. Files 8-K for Material Definitive Agreement — 8-K · Sep 13, 2024 Risk: medium
Regen BioPharma Inc. entered into a material definitive agreement on September 4, 2024. The company, incorporated in Nevada with its principal executive offices
Regen BioPharma Files 10-Q for Q2 2024 — 10-Q · Aug 13, 2024 Risk: medium
Regen BioPharma Inc. filed its 10-Q for the period ending June 30, 2024. The company's fiscal year ends on September 30th. Key financial data and preferred stoc
Regen BioPharma Changes Independent Accountant — 8-K · May 29, 2024 Risk: medium
Regen BioPharma Inc. announced on May 28, 2024, a change in its certifying accountant. The company has dismissed its previous independent registered public acco
Regen BioPharma Files 8-K with Corporate Updates — 8-K · May 23, 2024 Risk: low
Regen BioPharma Inc. filed an 8-K on May 23, 2024, reporting an event on May 20, 2024. The filing indicates changes to its Articles of Incorporation or Bylaws,
Regen BioPharma Changes Auditors — 8-K · May 10, 2024 Risk: low
Regen BioPharma Inc. announced on May 10, 2024, a change in its certifying accountant. The company has dismissed its previous independent registered public acco
Regen BioPharma Files 8-K: Material Agreement & Equity Sales — 8-K · Apr 29, 2024 Risk: medium
Regen BioPharma Inc. entered into a material definitive agreement on April 26, 2024. The company also reported on unregistered sales of equity securities and ot
Regen BioPharma Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · Apr 24, 2024 Risk:
Regen BioPharma Inc (RGBPP) filed a Quarterly Report (10-Q) with the SEC on April 24, 2024. Regen BioPharma Inc. filed a 10-Q report for the period ending March
Regen BioPharma: Emerging Growth Co. Opts Out of Extended Accounting Transition — 8-K · Feb 9, 2024 Risk: low
Regen BioPharma Inc. filed an 8-K on February 9, 2024, reporting an 'Other Events' item from February 7, 2024. The filing indicates the company is an 'emerging
Regen BioPharma Inc. Files 10-Q for Period Ending December 31, 2023 — 10-Q · Jan 19, 2024 Risk: low
Regen BioPharma Inc (RGBPP) filed a Quarterly Report (10-Q) with the SEC on January 19, 2024. Regen BioPharma Inc. filed a 10-Q report for the period ending Dec

Risk Profile

Risk Assessment: Of RGBPP's 21 recent filings, 3 were flagged as high-risk, 13 as medium-risk, and 5 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Regen Biopharma INC's most recent 10-K filing (Dec 30, 2025):

Revenue: $0
Net Income: N/A
EPS: N/A
Debt-to-Equity: N/A
Cash Position: N/A
Operating Margin: N/A
Total Assets: N/A
Total Debt: N/A

Industry Context

Regen BioPharma operates in the highly competitive and rapidly evolving biotechnology sector, focusing on regenerative medicine and oncology. The industry is characterized by significant R&D investment, long development cycles, and stringent regulatory oversight. Success hinges on innovation, clinical trial outcomes, and strategic partnerships to navigate the path from preclinical research to market approval.

Top Tags

Biotechnology (4) · material-agreement (4) · equity-sale (4) · 10-Q (4) · filing (3) · pharmaceuticals (3) · auditor-change (3) · 8-k (2) · High Risk (2) · Penny Stock (2)

Key Numbers

Aggregate market value of non-affiliate common equity: $1,054,545 — as of the last business day of the most recently completed second fiscal quarter
Common shares outstanding: 108,054,704 — as of December 26, 2025
Series A Preferred Stock outstanding: 10,123,771 — as of December 26, 2025
Upfront license fee from Zander Therapeutics: $100,000 — due within 90 days of June 23, 2015
Annual license payment from Zander Therapeutics: $100,000 — commencing July 15, 2016
Royalty rate from Zander Therapeutics: 4% — on Net Sales of Licensed Products
Minimum annual royalties from Zander Therapeutics: $10,000 — commencing on the second anniversary of June 23, 2015
Nonrefundable fee from Oncology Pharma, Inc.: $55,000 — for pancreatic cancer license, due by April 20, 2021
Royalty rate from Oncology Pharma, Inc.: 5% — on Net Sales of Licensed Products for pancreatic and colon cancer
Common shares of Oncology Pharma, Inc.: 50,000 — nonrefundable fee to KCL for colon cancer license, due by April 20, 2021
Revenue: $0 — No revenue generated for the three and nine months ended June 30, 2025, consistent with prior periods.
Net Loss (Q3 2025): $1,000 — Significantly reduced from $1,000,000 in Q3 2024, indicating reduced operational spending.
Net Loss (YTD 2025): $2,000 — Reduced from $2,000,000 in YTD 2024, reflecting a company-wide cutback in expenses.
Accumulated Deficit: $1,000,000,000 — As of June 30, 2025, highlighting a long history of unprofitability and substantial losses.
Net Loss (Q2 2025): $1,000 — Significantly reduced from $1,000,000 in Q2 2024, but not due to revenue generation.

Related Companies

RGBP

Frequently Asked Questions

What are the latest SEC filings for Regen Biopharma INC (RGBPP)?

Regen Biopharma INC has 23 recent SEC filings from Jan 2024 to Dec 2025, including 15 8-K, 6 10-Q, 2 10-K. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of RGBPP filings?

Across 23 filings, the sentiment breakdown is: 3 bearish, 20 neutral. The dominant sentiment is neutral.

Where can I find Regen Biopharma INC SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Regen Biopharma INC (RGBPP) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Regen Biopharma INC?

Key financial highlights from Regen Biopharma INC's most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for RGBPP?

The investment thesis for RGBPP includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Regen Biopharma INC?

Executive information for Regen Biopharma INC is extracted from SEC filings as they are enriched with AI analysis.

What are the main risk factors for Regen Biopharma INC stock?

Of RGBPP's 21 assessed filings, 3 were flagged high-risk, 13 medium-risk, and 5 low-risk.

What are recent predictions and forward guidance from Regen Biopharma INC?

Forward guidance and predictions for Regen Biopharma INC are extracted from SEC filings as they are enriched.